Healthtech & Wellness VC Funds

OpenSpace Ventures is a prominent venture capital firm based in Southeast Asia, known for its strategic investments in transformative tech companies across the region. Established in 2014, OpenSpace Ventures has backed notable companies like Gojek, Halodoc, and Love, Bonito, which have made significant impacts in their respective industries. The firm focuses on sectors such as fintech, healthcare, e-commerce, and digital media. Their portfolio includes companies like Lista, a financial management platform for individuals and small business owners in the Philippines; Lucence, a precision oncology company; and Nutrition Technologies, which produces sustainable insect-based proteins for agriculture. OpenSpace Ventures employs a hands-on approach, providing not only capital but also strategic guidance and operational support to help their portfolio companies scale and succeed. They manage several funds, including those focused on Series A/B and mid-stage growth investments, and are recognized for their deep expertise and active involvement in the Southeast Asian startup ecosystem​.

OpenView Venture Partners, based in Boston, is a leading venture capital firm focused on expansion-stage B2B software companies. Founded in 2006 by Scott Maxwell, OpenView specializes in product-led growth (PLG), backing high-potential startups in sectors like SaaS, cloud computing, and productivity software. Notable investments include companies like Calendly, Expensify, and UserTesting, which have scaled into industry leaders with the firm’s support. OpenView typically invests between $5 million and $15 million, focusing on companies with $2 million to $20 million in revenue. Their strategy revolves around more than just capital; they provide operational expertise, assisting with areas like pricing, go-to-market strategy, and talent acquisition. Their value-add model means they work closely with portfolio companies to optimize growth and operational efficiency, helping founders build sustainable and scalable businesses. Geographically, OpenView invests primarily in North America, with a keen eye for businesses that are ready to transition from early traction to full-scale market dominance. The firm is known for its deep expertise in the enterprise software space and is selective about partnering with companies that align with its product-led growth thesis. The leadership team, including key partners like Blake Bartlett and John McCullough, are hands-on with portfolio companies, often playing a pivotal role in key hires and strategic decisions. OpenView is particularly known for its content and community efforts, offering valuable industry insights and resources to help software leaders grow faster.

Operator Collective, founded in 2019 and based in Palo Alto, California, is a venture capital firm that leverages a unique model combining capital with a community of experienced operators. The firm focuses on investing in early-stage B2B companies, primarily in enterprise tech sectors such as SaaS, AI, and data analytics. Notable portfolio companies include Ironclad, Guild Education, Faros AI, and Hex Technologies. Operator Collective typically invests in seed and Series A rounds, with an average investment size of $3M to $20M. The firm has built a reputation for its diverse and inclusive approach, drawing on the expertise of over 200 operator LPs who have scaled successful tech companies like Atlassian, Guild Education, and Toast. The team, led by founder Mallun Yen, brings extensive experience from the tech industry, providing hands-on support to portfolio companies. This support includes leveraging their substantial networks for strategic introductions and advice on scaling operations​. Operator Collective's investment strategy emphasizes not only financial backing but also operational expertise, aiming to drive growth and innovation in its portfolio companies​.

Operator Partners is a venture capital firm that uniquely operates with its own capital, investing in technology companies from the pre-seed to Series B stages. Founded and led by experienced entrepreneurs, the firm provides support beyond financial investment, focusing on helping companies with business building and scaling challenges that arise between board meetings. Operator Partners has a hands-on approach, offering guidance based on their own entrepreneurial experiences. They engage with founders on various aspects such as product development, customer acquisition, fundraising, recruiting, and establishing organizational culture. The firm does not lead funding rounds or take board seats but assists in finding lead investors if needed. The team includes General Partners Amit Avner, Gil Shklarski, Nat Turner, and Zach Weinberg, along with Partner Olivia Benjamin. This team brings extensive expertise from founding and scaling successful companies themselves, making them well-equipped to support their portfolio companies effectively.

Optum Ventures is an independent venture capital firm founded in November 2017 as a strategic partnership between UnitedHealth Group and its Optum subsidiary. Headquartered in Boston, Massachusetts with a second office in Menlo Park and London presence, the firm launched with an initial $250 million commitment and has since scaled to over $2 billion in assets under management across six successive funds. Its mission is to back the next generation of healthcare innovation, investing stage-agnostically from seed through growth equity in companies at the intersection of technology and healthcare. Partners include A.G. Breitenstein, Virginia McFerran, and Heather Roxborough. Optum Ventures leads rounds and its thematic priorities include digital health, data analytics, value-based care delivery, healthcare enterprise software, clinical AI, fintech and insurtech applied to healthcare, and enabling health-system infrastructure. The firm has deployed capital into more than 120 companies and holds five unicorns: Ambience, an AI ambient scribe company; DispatchHealth; and LetsGetChecked, among others. Recent activity includes Risa Labs in January 2026 as the most recent disclosed investment; Reema Health at Series B in December 2025; Headstart, an ABA autism-care platform backed in 2025; and CoPlane, which raised a $14 million seed round in 2025 for AI-native ERP workflow automation. Optum Ventures' differentiation lies in its deep commercial connectivity to UnitedHealth Group — the largest US health insurer and services company. Portfolio companies gain access to health plans, providers, employers, and patients through the UHG network, as well as Optum's health-services commercialization expertise. This combination of financial capital and strategic distribution makes Optum Ventures one of the most consequential healthcare-focused CVCs in the market.

Orange Ventures MEA is the Middle East and Africa-dedicated arm of Orange Ventures, the EUR 350 million global corporate venture capital fund of Paris-based telecom major Orange S.A. Operating from Cairo, Egypt since 2017, the unit manages EUR 50 million earmarked exclusively for the MEA region and maintains additional presence in Dakar, Senegal. As a benchmark technology investor across Africa and the Middle East, the fund deploys capital through two distinct streams: MEA Champions, which backs Series A and later growth-stage companies with proven traction, and MEA Seed, which finances very early-stage startups with tickets of up to EUR 200,000 and an explicit goal of backing 100 seed companies by 2025 across countries where Orange operates. The firm's 29 investments span fintech, e-commerce, cybersecurity, digital enterprise, consumer internet, gaming, edtech, and healthtech. Portfolio companies include 7Keema (Egypt, e-health nursing services), Chari.ma (Morocco, B2B local-shop marketplace), Dabchy (Tunisia, peer-to-peer secondhand fashion marketplace), and Socium, backed through the MEA Seed program in late 2024. In May 2024, Orange Ventures and Digital Africa signed a co-investment partnership focused on startups emerging from the Orange Digital Centers network. Asma Ennaifer, Executive Director for CSR and the Orange Digital Center program across Orange MEA, provides strategic leadership for the broader Orange ecosystem that feeds into the fund. Orange Ventures MEA functions as both a financial investor and a strategic gateway, offering portfolio companies access to Orange's commercial distribution, telecom infrastructure, and pan-African operator relationships across countries in sub-Saharan Africa, North Africa, and the Middle East.

Oraseya Capital is a Dubai-based VC fund launched in 2023 by the Dubai Integrated Economic Zones Authority. Backed by $136 million, it invests in UAE startups from pre-seed to Series B. The focus is on high-growth areas like fintech, edtech, digital health, AI, logistics, and the future of work. As a government-linked fund, it’s part of Dubai’s push to back local founders and build a strong tech ecosystem.

OrbiMed is a leading healthcare-focused investment firm based in New York City, established in 1989. It manages over $18 billion in assets across various investment strategies, including public equity, private equity, and private credit/royalty investments. OrbiMed invests globally in companies spanning the healthcare sector, from biopharmaceuticals to medical devices and healthcare services. OrbiMed’s portfolio includes notable companies like Guardant Health, Adaptive Biotechnologies, and Apollomics, showcasing its strong presence in the biotech and medical device sectors. The firm is known for its ability to back innovative startups and has been instrumental in bringing over 60 new healthcare therapies to market​ ​. For startups and established companies looking to connect with OrbiMed, it is beneficial to demonstrate innovative healthcare solutions with strong potential for market impact. The firm typically leads investment rounds and provides significant strategic support to help companies grow into market leaders.

Oregon Venture Fund (OVF) is Portland's largest and most active early-stage technology investor, founded in 2007 as the Oregon Angel Fund and rebranded in 2018 to reflect its evolution into a fully institutional venture vehicle. Managing Partner Eric Rosenfeld co-founded the firm and leads a platform that has grown to approximately $250 million in cumulative AUM, deploying $15 to $20 million annually through an annual-vintage model. Each year OVF forms a new limited partnership drawing from a community of 180-plus accredited venture partners who serve as both LPs and as active advisors, operators, and deal introducers for portfolio companies. The fund focuses exclusively on Oregon and Southwest Washington companies across stages from seed through Series B, with initial checks of $500,000 to $4 million and total reserves of up to $10 million per company. OVF leads rounds and has backed over 70 portfolio companies, including Absci (NASDAQ: ABSI, the largest biotech IPO in Greater Oregon history at $230 million), Jama Software, Elemental Technologies, Brandlive, Salt and Straw, Wildfang, Conveyor, Hydrolix, and Lumen Learning. Through 2021 the firm reported a 34 percent average annual rate of return and a 3.5x gross multiple. OVF invests across software, biotech, health technology, food and beverage, and AI, reflecting the diverse character of the Pacific Northwest technology ecosystem it helped build. The firm's community-LP model means that portfolio founders gain not just capital but introductions to operators and executives with deep Pacific Northwest networks, giving OVF a differentiated value proposition relative to coastal generalist funds.

Origins Fund is a unique venture capital firm that specializes in backing consumer technology startups from pre-seed to Series A. What sets Origins apart is its strategy of combining financial investment with the power of social influence. The fund's limited partners include high-profile athletes and celebrities who collectively have over 160 million social media followers. This provides an "unfair advantage" to the startups in its portfolio by significantly boosting their visibility and growth potential. Origins typically invests between $100,000 and $500,000 per startup and reserves additional capital for follow-on investments in the most promising companies. The fund focuses on category-defining consumer businesses, particularly those that can benefit from the massive influence and reach of its celebrity LPs. The fund's co-founders, including former French football star Blaise Matuidi, are based in global hubs like Miami, New York, and Paris, allowing Origins to maintain a diverse and internationally connected portfolio. Notable investments include companies like Upway, a marketplace for reconditioned e-bikes, and Moka.care, a corporate mental health solution.

Orion Venture Partners is an early-stage venture capital firm headquartered in Palo Alto, California, operating the Orion Opportunity Fund I, established in 2019. Though the current fund vehicle was formed that year, the underlying investment team has been active since 2001, having invested in 43 companies with approximately $889 million of cumulative capital deployed and an 87 percent average IRR across trade-sale and IPO exits. The firm positions itself as a differentiated, hands-on investor working alongside founders to scale into category-defining platforms, describing its partners as 'early investors, long-term partners.' The fund's investment parameters include a five-year investment period, early-stage checks of $100,000 to $500,000, and growth-stage checks of $1 million to $5 million, with a target ownership of 7 percent or more per position. Geographic focus spans Greater China and the United States, with a particular emphasis on cross-border technology plays. Thematic priorities include artificial intelligence, medical technology, media and content, retail services, mobile content, wireless and telecom infrastructure, and sports technology. From the 2019 vintage, Orion has made 10 disclosed investments, with notable portfolio companies including Avesha (Kubernetes application services), Verana Networks (5G radio access network equipment), and Paw Paw (consumer food products). Orion Venture Partners takes a long-duration approach to company building, leveraging its partners' two-decade track record of cross-border investing to provide founders with both capital and strategic access across the US and Asia-Pacific markets.

ORIX Growth Capital (formerly ORIX Venture Finance and ORIX Ventures) is the growth-finance and venture-debt business of ORIX Corporation USA, the US hub of Tokyo-listed international financial services group ORIX Corporation, which operates across 30 countries. Founded in 2001 and headquartered in New York with additional presence in Dallas, the group rebranded to ORIX Growth Capital to better reflect its positioning as a specialist provider of debt and equity capital to venture-backed, high-growth companies rather than a traditional equity VC. The platform is led by Jeff Bede as Head of Growth Capital, alongside Managing Directors David Orlandella and Benjamin Wu, who heads the East Coast practice. Orix Growth Capital is an enterprise-value lender that scales individual facilities from $5 million to $100 million and deploys across the full capital stack, including senior secured unitranche, second-lien facilities, subordinated venture debt, and equity co-investments. Typical terms include five-year maturities, extended interest-only periods, and delayed-draw capability. Sector focus centers on technology and healthcare, spanning SaaS, software, biotech, fintech, and data analytics. Since 2001 the group has provided approximately $2.5 billion in financing to more than 200 companies and has recorded 45 portfolio exits. Recent activity includes a debt facility for Piano Software alongside Updata Partners' Series D equity round in February 2025. The firm leads transactions and provides capital-structure solutions that complement rather than compete with equity investors, giving founders growth runway with flexible repayment structures designed for SaaS and healthcare business models.

Oriza Ventures is a venture capital fund that focuses on early-stage technology investments, primarily in North America. Founded by seasoned entrepreneurs and investors, Oriza Ventures supports startups with disruptive technological pursuits and innovative business ideas. The firm's portfolio spans various industries, including artificial intelligence, big data, Internet of Things, consumer internet, and medical and health products. The team at Oriza Ventures includes founding partners John Yu, Alex Liang, and Yao Xiao, who bring extensive experience in venture capital and entrepreneurship. They leverage their backgrounds to provide strategic guidance and resources to their portfolio companies. Oriza Ventures' portfolio features a diverse range of companies such as Ayla Networks, an IoT platform for smart home appliances; Bolt, an online checkout platform; and InterVenn Biosciences, which uses AI-driven mass spectrometry for medical applications.

Orkla Ventures is the venture capital arm of Orkla Group, a leading supplier of branded consumer goods based in Oslo, Norway. This corporate venture fund focuses on technology, digital platforms, and software solutions with a particular interest in digital health, sustainability, food tech, and SaaS solutions. Orkla Ventures aims to leverage its industry expertise to invest in innovative startups that align with Orkla’s business domains and strategic interests. Orkla Ventures typically invests in seed and early-stage companies, with a commitment to fostering growth and supporting innovative solutions. The firm has made significant investments, including in the medical chatbot service Your.MD, which helps ease the burden on healthcare systems by providing pre-primary care and digital health solutions​.

Orlando Health Ventures is the corporate venture capital arm of Orlando Health, one of Central Florida's largest nonprofit integrated healthcare systems, established in 2018 and based in Orlando, Florida. The unit sits inside the Orlando Health Strategic Innovations group alongside The Foundry, Orlando Health's internal innovation and rapid-prototyping engine, giving portfolio companies direct access to clinicians, operating executives, and service-line leaders for evaluation, piloting, and commercial validation. The fund targets early-stage companies whose technologies have the potential to transform care delivery, clinical workflows, and patient outcomes. Orlando Health Ventures has made approximately nine disclosed investments concentrated in medical devices and digital health. Portfolio companies include 410 Medical (rapid IV medication delivery, with a Series B-II round in March 2025 as the firm's most recent disclosed investment), Biostable Science and Engineering (Austin-based heart-valve repair device as an alternative to replacement, with roughly $1.25 million deployed), and Vesalio (neurovascular thrombectomy devices whose NeVa VS system launched at Wellstar Health System in Atlanta). The fund participates in seed through Series B rounds alongside peer health-system corporate venture arms such as UPMC Enterprises. What distinguishes Orlando Health Ventures is its combination of clinician-led diligence and operational pilot capability. Portfolio companies can run structured pilots within the Orlando Health system, gaining real-world evidence and commercial traction while the fund's investment committee evaluates growth trajectory and return potential. The result is a capital partner that brings both funding and a credible path to enterprise healthcare customers.

OS Fund, established in 2014 by Bryan Johnson, is a venture capital firm that invests in early-stage science and technology companies. The firm focuses on sectors such as genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics. The goal is to support companies that are developing groundbreaking technologies and solutions to solve significant real-world challenges​. Bryan Johnson, who co-founded the fund, initially invested $100 million of his own money after selling his previous company, Braintree, to PayPal for $800 million. The fund seeks out entrepreneurs who are future-oriented and possess the ambition to create a better future for humanity​. OS Fund has a strong portfolio, including companies like Ginkgo Bioworks, Atomwise, and Verge Genomics. These companies are at the forefront of innovation, working on projects such as self-fertilizing crops, storing data in DNA, and designing new proteins.

Osage Venture Partners (OVP) is a Philadelphia-based venture capital firm that specializes in early-stage investments in B2B software companies. The firm primarily focuses on companies driving innovation in the future of work and education sectors. Since its inception, OVP has invested in over 30 companies, with a strong preference for those with recurring revenue models and deep domain expertise. Notable investments in their portfolio include companies like Sidecar, RiskLens, and ExecOnline. OVP typically invests in post-revenue companies with a revenue run rate between $500,000 and $3 million, focusing mainly on Seed and Series A rounds. They have a hands-on approach, often leading or co-leading investments and joining the boards of their portfolio companies. OVP emphasizes the importance of partnerships, leveraging their extensive network of technology executives and industry experts to support the growth and success of the companies they invest in. Their team is comprised of seasoned investors and former operators who provide strategic guidance and operational support to entrepreneurs.

OSF Ventures is the corporate venture capital arm of OSF HealthCare, a 15-hospital nonprofit integrated health system operating across Illinois and Michigan. Founded in 2015 and headquartered in Peoria, Illinois, OSF Ventures sits within OSF Innovation and invests financially, operationally, and strategically in healthcare companies whose technologies can improve patient outcomes, enhance patient experience, and reduce the cost of care. Mayank Taneja, Vice President of Venture Investments, leads a seven-person team across three successive fund vintages that have grown cumulative AUM to $250 million, anchored by Fund III, a $100 million vehicle launched in January 2022 with a thesis tilt toward alternative care modalities and healthcare workforce retention. The firm participates as a syndicate member at Series A through growth stages and has made approximately 37 investments spanning health information technology, medical devices, therapeutics, diagnostics, and technology-enabled care delivery. The portfolio has produced notable exits including Current Health (acquired by Best Buy in 2021), Health Catalyst (NASDAQ IPO in 2019), and SilverCloud Health (acquired by Amwell in 2021). Recent deployments include Hellocare.ai, Cala, ShiraTronics, Cardiosense ($15.1 million Series A for an AI heart disease biomarker platform), 410 Medical ($6.3 million Series B for pediatric sepsis), and Digital Diagnostics ($75 million Series B, autonomous AI diagnostics). OSF Ventures brings more than just capital to portfolio companies. Its status as an active operating health system means founders gain access to clinical validation environments, practitioner networks, and patient populations that can meaningfully accelerate regulatory and commercial timelines, making the fund a strategic partner in addition to a financial backer.

OSK Ventures International Berhad (OSKVI) is a publicly listed venture capital and private equity firm established in 2000 and headquartered in Kuala Lumpur, Malaysia, trading on Bursa Malaysia under ticker 0053.KL. As the VC and PE affiliate of OSK Holdings Berhad, the platform provides patient growth capital to Malaysian and Southeast Asian technology companies across early-stage, late-stage, expansion, growth equity, and venture debt vehicles. A central pillar of the group is OSK-SBI Venture Partners, a 2018 joint venture with Tokyo-listed SBI Holdings, which invests out of successive Malaysia-domiciled funds and has managed multiple vehicles totaling $220 million since 2011. OSK Ventures has made approximately 55 investments across an active portfolio of 37 companies, spanning fintech, B2B SaaS, healthtech and telemedicine, e-commerce, ESG and carbon-emissions monitoring, compliance software, decentralized finance, digital asset exchange software, and enterprise technology. Portfolio companies include Endowus (Singapore digital wealth management, which participated in a $50 million-plus strategic round in January 2025), Doctor Anywhere, CompAsia, and AllRites. The fund's geographic focus spans Southeast Asia broadly, with Malaysia at the center. OSKVI's public listing on Bursa Malaysia, combined with its partnership with SBI Holdings, gives the firm a distinctive combination of local market credibility, institutional-grade governance, and access to Japanese corporate and financial networks. Founders backed by OSK Ventures gain a strategic investor with deep regional operating relationships and the institutional weight of a listed entity alongside the entrepreneurial connectivity of SBI's broader ecosystem.

OTB Ventures is a European venture capital firm based in Amsterdam, focused on deep tech startups across Central and Eastern Europe. They specialize in sectors like space tech, artificial intelligence, automation, fintech, and cybersecurity. Founded by Adam Niewinski and Marcin Hejka, OTB Ventures aims to support founders with unique IP and global ambitions by providing early growth funding. Their portfolio includes notable companies like ICEYE, which specializes in radar satellite imagery; Silent Eight, an AI platform for financial crime detection; and Fractory, an automated on-demand metal manufacturing platform. Other significant investments include Turnkey Lender, an embedded lending platform, and Hydrosat, which provides thermal infrared imagery for analytics. OTB Ventures supports their portfolio companies with business and partner introductions, expertise in sales channels, and strategic guidance for international expansion. They are also involved in syndicating additional financing and preparing companies for successful exits.

OTV (formerly Olive Tree Ventures) is a global specialist venture capital firm exclusively dedicated to digital health, founded in 2015 and headquartered in Tel Aviv, Israel with additional offices in New York, Montreal, and Shanghai. Co-founded by General Partners Mayer Gniwisch, Amir Lahat, and Alejandro Weinstein, who together bring backgrounds spanning healthcare, technology, private equity, and financial services, the firm is widely recognized as Israel's only major VC whose primary investment focus is digital health. Partner Manor Zemer complements the founding team. OTV closed a dedicated $170 million digital-health growth fund in December 2020, anchoring its international expansion including the opening of its Asia office in Shanghai. The firm leads rounds across 45 investments and covers the full arc of digital health: telemedicine and virtual care, genomics, AI-powered clinical decision and diagnostics platforms, digital biomarkers, precision medicine, and next-generation medical-device software. Notable portfolio companies include TytoCare (remote examination kit, whose $50 million round OTV led alongside Insight Partners and Qualcomm Ventures) and Scopio Labs ($16 million Series B that OTV led in December 2023, advancing digital microscopy and AI pathology). Realized exits include Lemonaid Health (acquired by 23andMe) and Emedgene (acquired by Illumina). OTV focuses particularly on companies reaching commercial maturity, partnering with founders to navigate regulatory, reimbursement, and enterprise sales challenges across five continents. Its combination of Israeli innovation sourcing, US capital-market relationships, and Asian commercial networks makes it a genuinely global platform for digital health at growth stage.

OurCrowd, founded in 2013 and headquartered in Jerusalem, is a leading global venture capital platform. It offers accredited investors access to pre-vetted startups, exclusive venture funds, and alternative investments. The firm’s portfolio covers sectors such as healthcare, AI, robotics, energy, and fintech, with notable investments in Beyond Meat, JumpCloud, and Lemonade. Beyond Meat, a leader in plant-based foods, and Lemonade, an AI-driven insurance company, both had successful IPOs and continue to thrive. OurCrowd’s investment strategy involves thorough due diligence and active support for portfolio companies, ranging from seed to growth stages. They typically invest between $1 million and $5 million, offering strategic guidance and access to a global network of co-investors and operational support​. The firm operates globally, with a strong presence in Israel and the U.S., and investments in Europe, Asia, and Latin America. This global reach allows them to tap into diverse markets and innovative ecosystems. Led by CEO Jon Medved, OurCrowd’s team includes investment professionals across multiple offices worldwide, ensuring a comprehensive approach to emerging technologies and market opportunities. Startups seeking investment should highlight their innovation, scalability, and market potential, approaching OurCrowd through their network or platform to increase funding chances

Outbound Ventures, founded in 2015 and based in New York, focuses on early-stage investments in tech-enabled consumer-facing companies. They have made 54 investments and have had 16 successful exits, including companies like Mented Cosmetics, Hydra Studios, and Fleur Marché. The firm is led by co-founders Jimmy Thermiotis, Luis Gonzalez, and Nael Rasamny. Outbound Ventures prioritizes companies with self-aware and adaptable founding teams and leverages their extensive network across Latin America, the U.S., and the U.K. to support the growth of their portfolio companies. Notable investments include Treinta, a fintech company in Colombia; Nabis, a logistics software for the cannabis industry; and Moonshot Brands, a company focused on e-commerce and consumer goods. Their investment strategy typically involves rounds ranging from seed to Series A, with an average round size of $8 million.

Outlierz Ventures is a pioneering Africa-focused seed venture capital firm founded in 2017 by Kenza Lahlou and headquartered in Casablanca, Morocco, with additional presence in San Antonio, Texas and Egypt. The firm's mission is to channel capital, knowledge, and networks to outstanding founders solving Africa's most pressing challenges through technology that transforms traditional industries. A core team of six, including four partners, works across Africa's main technology hubs, with co-investment relationships alongside peers such as Orange Ventures to expand deal capacity and follow-on support. Outlierz leads rounds at pre-seed, seed, and pre-Series A stages across 22 investments into 17 portfolio companies, concentrating on fintech, insurtech, logistics, agritech, and health tech. The firm has recorded three portfolio acquisitions to date: Traction Apps (acquired by OmniRetail in October 2024), WaystoCap, and Tousfacteurs. Active portfolio companies include Socium (HR SaaS for Francophone Africa SMEs, which raised a $5 million Seed-plus round in April 2025 as the firm's most recent investment), Wattnow (energy efficiency, $3.5 million-plus pre-Series A in November 2024), Terraa (Morocco agritech B2B marketplace, $1.5 million pre-seed in September 2024), Healthlane, and Freterium. Outlierz takes an active, hands-on role with its founders, providing not only capital but also strategic introductions, technical support, and connectivity across the African startup ecosystem. By backing companies at the earliest stages and staying committed through follow-on rounds, the firm builds long-term relationships designed to help founders scale from local traction to continent-wide impact.

Outsiders Fund, founded in 2020 and based in New York, focuses on early-stage investments in disruptive technologies. The fund backs founders challenging traditional industries with innovative solutions. Outsiders Fund has a diverse portfolio across various sectors, including enterprise software, healthcare, cybersecurity, and aerospace. Notable investments include RaySecur, which provides mail and package security solutions using mmWave imaging technology; Casana, which offers remote patient monitoring via a smart toilet seat; and Dyania Health, which matches patients for clinical trials. Another significant investment is in Apex, a company focused on spacecraft manufacturing​. The fund typically invests in seed and early-stage rounds, with an average round size of $11M. Recent investments include Gradial, a generative AI content creation platform, and PaintJet, a robotics company specializing in painting commercial spaces. Led by Managing Partner Theodore Seem and supported by a team of experienced professionals, Outsiders Fund aims to partner with founders to drive growth and innovation in their respective fields. Their approach involves close collaboration with portfolio companies, providing strategic guidance and facilitating key industry connections.

Outsized Ventures is a venture capital fund based in London, specializing in deep tech and frontier technology startups that aim to tackle the world's most pressing challenges. The fund takes a unique approach by prioritizing people over technology, focusing on bold innovators who are not afraid to push boundaries. Notable investments include companies like Emitwise (carbon accounting software), Hoxton Farms (cultivated fat for meat alternatives), and Kernal Biologics (mRNA therapeutics), reflecting their commitment to groundbreaking science and technology. Outsized Ventures primarily invests in Europe, with a clear focus on early-stage ventures. Their strategy is founder-friendly, offering quick, transparent investment processes, sometimes closing deals within 48 hours. They often invest between fundraising rounds, helping founders maintain momentum without the distraction of constant fundraising. The team is led by experienced investors like Max, a former corporate lawyer and venture capitalist with extensive experience across Europe, Africa, and Asia, and Rod, a seasoned investor with a strong background in bioengineering startups. Outsized Ventures typically leads funding rounds and is known for offering "clean and unfussy" terms, making them an attractive partner for ambitious entrepreneurs aiming to make a significant impact. If you’re a visionary founder with a big dream, they’re the kind of investor who will back you all the way.

Outward VC is a London-based early-stage venture capital firm founded in 2017 by Co-Founders and General Partners Kevin Chong and Devin Kohli. Originally launched as the Outward Venture Capital Fund of Investec Bank, the firm has since grown into an independent platform dedicated to fintech and adjacent sectors, including healthcare, education, property, legal services, AI, and insurance. Outward's thesis holds that fintech extends well beyond traditional financial services and that the future of finance is more open, embedded, and intertwined with society-shifting challenges. The firm typically leads rounds up to GBP 5 million, investing at least 50 percent of the round, and reserves significant follow-on capital for portfolio companies. Outward leads rounds at pre-Series A stage and has backed approximately 100 founders to date. Portfolio highlights include Bud ($80 million Series B), Curve (GBP 133 million Series C), Peppy Health ($45 million Series B), Vauban (acquired by Carta), Clearglass, Exate, Orbital Witness, and Supercede. In September 2024 the firm announced the GBP 51 million first close of Fund II, anchored by a GBP 30 million cornerstone from the British Business Bank's Enterprise Capital Funds programme, with a target of GBP 100 million at second close. Recent Fund II investments include a GBP 2.5 million Seed round into Lombard-lending fintech Firenze in March 2025 and Steward AI in March 2026. Outward VC combines high conviction with meaningful ownership, taking a concentrated approach that allows it to dedicate real time and resource to each portfolio company. The firm's roots in the Investec network and its close relationship with the British Business Bank give founders access to institutional financial relationships alongside hands-on operating support.

Overlooked Ventures is a venture capital firm founded in 2021, based in Columbus, Ohio, and focused on investing in early-stage companies led by historically underrepresented founders, particularly women, people of color, and other overlooked communities. Their goal is to break down barriers and promote diversity within the tech and startup ecosystems by providing capital, mentorship, and support to promising entrepreneurs. The firm, led by founding partners Brandon Brooks and Janine Sickmeyer, prioritizes sectors like health tech, fintech, climate tech, and social impact startups. With check sizes ranging from $150,000 to $1 million, Overlooked Ventures invests primarily in pre-seed, seed, and Series A stages. Their portfolio includes companies such as CarpeDM, Lalo, and Blooming Health, reflecting their focus on innovation and inclusivity. Overlooked Ventures aims to address the gaps in funding for diverse founders, helping them access resources and support that historically have been unavailable to them​.

AngelList, a prominent platform for startup investments, has facilitated investments in over 2,698 startups through its innovative syndicate and fund structures. Some of its notable investments include companies like Brex, Postmates, Cruise, and PillPack, which have grown significantly in their respective industries. AngelList offers various investment opportunities, including traditional funds, syndicates, and rolling funds, allowing investors to back startups on a deal-by-deal basis. The platform has democratized early-stage investing by providing individual accredited investors access to high-quality investment opportunities, often in collaboration with top-tier venture capital firms. For instance, AngelList has supported the growth of companies like Notion, Iterable, and MoonPay, providing them with the necessary capital to scale. Their full-service fund management capabilities streamline the investment process, from fund formation to managing cap tables and tax preparation, making it easier for new and experienced investors alike to participate in venture capital.

Overton Venture Capital, based in New York, is a woman-led early-stage VC firm with a sharp focus on investing in seed and early-stage companies that are driving transformative changes in technology and consumer behavior. The fund is particularly interested in sectors like digital health, fintech, edtech, and consumer products. Some of their notable investments include K Health, Stash, and Bringg, which highlight their commitment to backing companies with strong technological underpinnings poised for significant market disruption. The fund’s investment strategy revolves around identifying and supporting diverse founding teams that not only demonstrate innovative product vision but also exhibit fiscal discipline and rapid growth potential. Overton VC is known for its hands-on approach, leveraging the deep operational expertise of its partners to actively support portfolio companies in scaling their businesses. The team is led by co-founders Kerry Miller and Michael Nogen, both seasoned professionals with extensive experience in management consulting, corporate strategy, and entrepreneurship. They emphasize a collaborative, transparent partnership with founders, aiming to build businesses with sustainable, long-term value. Startups seeking investment are encouraged to have a clear path to revenue and a strong, integrity-driven leadership team.

Overwater Ventures is an early-stage venture capital firm based in San Francisco, founded and led by Kristina Simmons, a former partner at Andreessen Horowitz and Chief of Staff at Khosla Ventures. The firm focuses on investing in breakthrough technologies that positively impact human health and the planet. Overwater Ventures closed its $20 million debut fund in April 2023, with backing from institutional family offices, experienced founders, and prominent investors like Vinod Khosla. The fund primarily targets sectors such as digital health, biotech, AI, robotics, climate tech, and future food. Notable portfolio companies include Overstory, which reduces power outages and wildfires, and Conceive, a fertility technology firm. Overwater Ventures is committed to providing holistic support to its founders, addressing not just business needs like marketing and fundraising but also personal well-being, including mental health and stress management.

OVO Fund, established in 2013 and headquartered in Palo Alto, California, specializes in early-stage venture capital investments, particularly in the pre-seed and seed stages. The firm focuses on backing "scary early-stage startups" with innovative ideas across various capital-efficient sectors. Their typical check size ranges from $250,000 to $500,000, with significant reserves for follow-on investments before the Series A stage. OVO Fund has a diverse portfolio of over 90 technology startups, including notable companies like Palantir, Wish, RelateIQ, Signifyd, Piazza, Addepar, and Juniper Square. Recent investments include companies such as Suma Wealth, a fintech company, and Clayful, an e-learning and wellness platform for children. The firm is led by experienced investors such as Eric Chen and Ilse Calderon, who provide strategic support to help their portfolio companies grow and succeed. OVO Fund is currently investing out of its second fund, which is valued at $35 million.

Owl Ventures, founded in 2014 and based in Silicon Valley, is the largest venture capital firm dedicated to the education technology market, managing over $2 billion in assets. They specialize in investing across all stages from seed to late growth, focusing on transformative education companies. Notable investments include industry leaders like BYJU’s, MasterClass, Quizlet, and Newsela, which showcase their strategic emphasis on PreK-12, higher education, professional learning, and the intersection of EdTech with other sectors like FinTech and healthcare. Their investment strategy is hands-on, leveraging a global network of Limited Partners, distribution channels, and strategic partners to help portfolio companies scale effectively. Owl Ventures' approach includes support in talent acquisition, building syndicates, and navigating the education market's complexities. The firm is known for leading funding rounds and providing substantial check sizes, reflecting their active involvement in driving company growth and outcomes measurement. The team comprises experienced professionals like Managing Directors Ian Chiu, Tom Costin, Amit Patel, and Partner Malvika Bhagwat, each bringing deep domain expertise and a strong focus on education outcomes. Owl Ventures operates globally, with a strong presence in markets across North America, Europe, Asia, and Latin America, aiming to support innovative solutions that address the global skills gap and enhance educational accessibility and quality. Entrepreneurs seeking investment should note Owl Ventures’ preference for visionary leaders in EdTech, with an emphasis on scalable, impactful solutions. Approaching them with a clear demonstration of educational impact and market potential can significantly enhance partnership prospects.

Oxford Capital Partners, founded in 1999 and based in Oxford, UK, is a venture capital firm that focuses on investing in early-stage technology companies. The firm has invested approximately £500 million in over 100 businesses, emphasizing sectors such as fintech, digital health, artificial intelligence, and the future of retail. Their investment strategy leverages the UK's Enterprise Investment Scheme (EIS), providing tax advantages to investors and fostering innovation across the tech landscape. Oxford Capital seeks to back high-potential, disruptive technology with strong intellectual property or early signs of product-market fit. They typically aim to be the first institutional investor in these early-stage ventures, ranging from seed to Series A rounds. Their portfolio includes notable companies like Moneybox, Red Sift, and Attest. The firm prides itself on a hands-on approach, supporting founders with not only capital but also strategic guidance to help them achieve significant growth and scalability. The team, led by founder David Mott and including key members like Stephen Hampson and Chris Payne, brings a wealth of experience in venture capital and strategic investments. Oxford Capital's location in one of the world's leading knowledge clusters, Oxford, positions them advantageously to tap into cutting-edge innovations and support high-growth companies aiming to expand internationally.

Oxford Science Enterprises (OSE) is a venture capital firm deeply integrated with the University of Oxford, focusing on commercializing breakthrough scientific innovations. With a portfolio valued at over £2 billion, OSE invests in three core sectors: Life Sciences, Deep Tech, and Health Tech. It has partnered with over 200 leading academics from the university to build and support more than 80 high-impact companies. OSE’s strategy is to support early-stage ventures with long-term capital and hands-on expertise. Their investments span from biotechnology to quantum computing, with notable companies like Oxford Quantum Circuits, Ultromics, and Evox Therapeutics in the portfolio. OSE’s commitment to groundbreaking technologies is further emphasized by their mission to address global challenges such as health, food security, and sustainability. The firm is led by a distinguished team with deep ties to Oxford’s innovation ecosystem, including Jack Edmondson, the Chief Investment Officer, who has extensive experience managing large-scale investments at Oxford University Endowment Management. This alignment with Oxford enables OSE to identify and scale cutting-edge research into successful businesses. OSE’s model is designed to bridge the gap between academic discovery and market application, creating transformative companies that aim to improve human lives and drive future technological advancements.

Oxford Science Enterprises (OSE), previously known as Oxford Sciences Innovation, is a prominent investment company founded in 2015 with the mission to commercialize the cutting-edge research from the University of Oxford. OSE has raised over £850 million and invested around £775 million into over 45 core portfolio companies across three main sectors: Deep Tech, Life Sciences, and Health Tech. Notable investments include Vaccitech, the developer of the Oxford-AstraZeneca COVID-19 vaccine, Quantum Motion, and Beacon Therapeutics, which is advancing gene therapies for retinal diseases. OSE typically provides the first cheque to early-stage companies and supports them all the way to exit. Their strategy involves deep collaboration with Oxford University, leveraging the university's vast research capabilities to create transformative businesses. This partnership has resulted in over £1.4 billion in investment into university spinouts as of 2021, significantly increasing the scale and impact of Oxford's innovation ecosystem. The firm is committed to addressing some of the world's most significant challenges by supporting pioneering technologies and translating novel research into real-world applications. Their hands-on approach includes taking board seats and actively engaging with the founding teams to provide strategic guidance and operational support.

Oxford Technology is a venture capital firm that specializes in investing in early-stage technology-based businesses. They manage both SEIS (Seed Enterprise Investment Scheme) and EIS (Enterprise Investment Scheme) funds, providing up to £150k in seed funding for SEIS companies and up to £300k in follow-on funding for EIS companies. Their focus is on science, technology, and engineering startups, primarily within a 60-mile radius of Oxford to facilitate active involvement with the companies. Notable investments by Oxford Technology include OxWash, which is developing sustainable laundry solutions; Refeyn, pioneering mass photometry for single molecules; and HydRegen, creating bio-based manufacturing technologies. They have also invested in innovative companies like Neuroute, which aggregates data for clinical trial recruitment, and Covatic, enabling personalized content creation without the need for tracking IDs. Oxford Technology aims to maximize shareholder value by working closely with their portfolio companies to achieve successful exits and providing ongoing support. Their investment strategy not only leverages tax reliefs but also focuses on creating successful companies with significant long-term growth potential.

Ozmen Ventures is a Reno, Nevada-based early-stage venture capital fund founded in 2016 by Eren and Fatih Ozmen, the owners of Sierra Nevada Corporation (SNC), a global national-security contractor specializing in aircraft modification, space components and systems, cybersecurity, and eHealth with 5,000 employees across 40 offices. Kerem Ozmen serves as Principal and Managing Director, also a co-founder of 8090 Industries. Operating from the Innevation Center in downtown Reno, the fund was established to back innovative solutions to traditional problems in northern Nevada and beyond, with a deliberate goal of seeding a venture ecosystem in a state historically underserved by coastal capital. Sector focus spans aerospace, artificial intelligence, fintech, healthcare, advanced computing, and consumer internet, reflecting deep-tech adjacencies that align with the Ozmen family's SNC expertise. The firm has made approximately eight investments across seven portfolio companies. Notable portfolio names include FiscalNote, which listed on NASDAQ in December 2020 at a $219 million market cap and stands as Ozmen Ventures' only IPO exit to date, alongside Bloq, Luminous Computing, Self Lender, Covered, and ClickBio (laboratory consumables). Check sizes have ranged from seed through early Series A. Ozmen Ventures operates as a family-office vehicle with a concentrated, long-duration portfolio strategy. Its investment cadence is deliberately measured rather than high-frequency, reflecting a philosophy of making fewer, more deeply supported bets rather than diversifying broadly. The fund's strongest comparative advantage is its connection to SNC's national-security and space-technology customer base, which can provide portfolio companies with non-dilutive contracts and enterprise validation.

P101 Ventures, founded in 2013 and based in Milan, Italy, is a venture capital firm focusing on early-stage investments in the digital and technology sectors. With over 100 million euros under management, P101 is known for its commitment to nurturing innovative startups through capital, extensive networks, and strategic advisory. P101’s portfolio includes a variety of successful companies such as Tannico, an e-commerce platform for wine; BorsadelCredito.it, a peer-to-peer lending platform; and Cortilia, an online marketplace for fresh, local food products. The firm typically invests between 1 to 5 million euros per company and reserves additional capital for follow-on investments to support the continued growth of its portfolio companies. The firm's investment strategy involves active collaboration with founders, helping them design effective growth strategies and improve their ESG performance. P101 also leverages a strong network of strategic consultants, CEOs, and industry experts to provide deep operational and business development support​.

Pacific 8 Ventures is a Taiwan-based venture capital firm, primarily focusing on healthcare and disruptive technology platforms. Founded by Jack Liang, the firm targets early-stage companies, with a preference for being the first institutional investor. Pacific 8 Ventures invests in transformative technologies, especially those reshaping therapeutics, diagnostics, and broader health services. Their investment approach is global, with a strong emphasis on the U.S. market, where disruptive healthcare innovations are burgeoning​. Pacific 8 Ventures has built a diverse portfolio of companies at the forefront of healthcare innovation. Notable investments include Mammoth Biosciences, known for its pioneering work with CRISPR technology, and BillionToOne, which revolutionizes prenatal testing. They have also invested in companies like Fauna Bio, which uses mammalian genetic data for novel therapeutics, and Dorian Therapeutics, focused on anti-aging technologies. The firm is also involved in significant collaborations, such as Mammoth Biosciences' $1 billion partnership with Bayer. Pacific 8 Ventures is dedicated to helping companies navigate the challenges of scaling in the competitive healthcare landscape, leveraging deep expertise and strategic support to drive success.

Pacific Health Ventures (PAC.VC) is a Silicon Valley-based healthcare venture capital firm founded in 2019 and headquartered in Menlo Park, California. The firm is an early-stage investor focused exclusively on B2B health technology, backing software-as-a-service platforms that improve clinical outcomes, streamline clinical and administrative workflows, and unlock new revenue for healthcare providers, payers, pharma companies, and employer customers. Pacific Health Ventures operates with a lean two-person investment team and runs a strategy of matching early-stage startups with strategic industry partners that have relevant gaps in their technology and service offerings, coupling seed and Series A capital with distribution and validation from large health-system and enterprise partners. The firm has built a concentrated portfolio of five active companies. Notable investments include SafelyYou (AI-powered fall prevention for senior living), Limbix (adolescent mental-health digital therapeutics), and Sika Health (HSA and FSA payments infrastructure). Pacific Health Ventures has made four Series A investments with an average round size of $12.7 million. The firm's most recent activity includes the Feeling Great $12 million Series A and the Relief Cardiovascular Series A, both announced in January 2025. Pacific Health Ventures distinguishes itself through its partner-matching model, which creates a pathway for portfolio companies to land and expand within large health enterprise customers before scaling broadly. This approach reduces the cold-start problem endemic to health technology sales cycles and gives founders both the capital and the institutional relationships needed to cross the proof-of-concept threshold into recurring enterprise revenue.

Paladin Capital Group is a global venture capital firm based in Washington, D.C., with additional offices in New York, Silicon Valley, London, and Luxembourg. Since its inception in 2001, Paladin has managed over $1 billion in committed capital, investing in more than 65 companies across North America, Europe, Australia, and South America. The firm focuses on innovative technology, particularly in cybersecurity, which has become a primary area of expertise. Notable investments include Corellium, which specializes in mobile and IoT virtualization; Digital Shadows, a provider of cyber situational awareness; and Expel, a company offering transparent managed security. Other significant portfolio companies include RangeForce, which offers a cyber simulation and skills analytics platform, and Hack The Box, an online cybersecurity training platform. Paladin Capital Group employs a dual-use investment approach, leveraging its knowledge of both commercial and government markets to provide unique insights and opportunities for its portfolio companies. This strategy helps startups develop strategic partnerships, access new markets, and navigate financing options. The firm is committed to adding value beyond capital by supporting portfolio companies with strategic guidance and leveraging its extensive network to maximize returns. Paladin has been actively involved in numerous successful exits, including the sale of Hubble Technologies to KKR-backed NetSPI.

Pallasite Ventures is a venture capital firm that focuses on providing early-stage financing to high-growth companies across a variety of industries, including tech and consumer products. Founded in 2012 and based in Vancouver, Canada, Pallasite Ventures aims to fund companies whose leaders have the vision and skill to transform their markets. The firm is particularly active in Seed and Series A deals, offering investments ranging from $100,000 to $1.5 million USD and maintaining significant reserves to support their portfolio companies as they grow. The firm has invested in over 60 companies, including notable names like Dooly, Prescryptive, and CalypsoAI. Pallasite Ventures places a strong emphasis on adding value and providing support to its portfolio companies, ensuring they have the resources and freedom needed for long-term growth. The firm's investment focus spans multiple regions, including Vancouver, San Francisco, Boston, Denver, Chicago, and Toronto. Pallasite Ventures is led by Managing Partner Christopher Bissonnette, Ph.D., and operates with an agile and supportive approach, aiming to streamline decisions and provide strategic advice to its investments​.

Palm Drive Capital, headquartered in New York City with additional offices in San Francisco and Taipei, is a venture capital firm that specializes in early-stage investments. Founded in 2014, the firm primarily backs Seed and Series A tech founders across SaaS, AI, fintech, and e-commerce sectors. Their global approach underscores their belief that "innovators are everywhere," supporting startups from diverse geographical regions​. The firm has a notable portfolio, including investments in Deep Instinct, a leader in cybersecurity, and MoneyLion, a modern challenger bank. Palm Drive Capital has also achieved significant exits, such as those from Clover Health and Long Game, highlighting their success in identifying and nurturing high-potential startups​. Palm Drive Capital prefers a collaborative investment approach, frequently co-investing with other venture firms rather than leading rounds. Their strategy focuses on scalable solutions in high-growth markets, providing not only financial support but also strategic guidance through their extensive network. This approach has positioned them as a valuable partner for early-stage companies looking to scale efficiently. Led by co-founders Hendrick Lee and Seamon Chan, the team comprises experts like Catherine Cai and Nick Hsu, who contribute significant investment and operational expertise. For startups aiming to engage with Palm Drive Capital, demonstrating a robust product-market fit and a clear scalability plan is crucial. The firm values well-prepared pitches that highlight market opportunities and strategic growth plans​.

Palm Venture Studios is a turnaround-focused venture studio established in 2021 by the Palm Ventures family investment office, itself founded by Brad Palmer in 1992. Headquartered in Austin, Texas, with offices in Boston, Philadelphia, Las Vegas, Columbus, Hudson NY, and Salt Lake City, the firm pioneered what it calls 'second-chance' capital: investment in purpose-driven but financially stuck early-stage startups that have built real product traction yet run into a capital-structure wall. Palm's thesis recognizes that many promising companies are not failing on product but on cash flow, and that what they need is a combination of restructuring, fresh capital, and operational rebuilding rather than a standard growth check. Executive Chair Brad Palmer, who sits on the Project Drawdown board, co-founded the studio alongside Managing Partner Daniela Plattner. The firm concentrates on companies working on human and planetary health, spanning healthtech, sustainability, AI, and SaaS. Across its lifetime Palm has invested second-chance capital into more than 25 early-stage, mission-driven businesses. Notable portfolio companies include Camio, which built computer-vision and AI safety-monitoring technology deployed across 14 countries before hitting a near-death cash crunch and being restarted with Palm's backing, and Kashew, a SaaS platform helping resale businesses build digital storefronts that reportedly lifted reseller revenue by up to 20 percent in a single month. Palm Venture Studios takes meaningful ownership stakes and pairs patient capital with deep operational support, engaging at the governance and go-to-market level rather than simply writing a check. Its distributed multi-city footprint allows it to source overlooked opportunities outside the traditional coastal VC hubs.

Palo Santo is a venture capital firm specializing in psychedelic healthcare and therapies, with a mission to revolutionize mental health treatment. Founded in 2020, Palo Santo operates with a clear focus on advancing the development of psychedelic-based treatments for conditions like depression, PTSD, and addiction. With an initial fund of $35 million, the firm supports a wide range of companies working on groundbreaking solutions in biopharma, digital therapeutics, and healthcare services. Their portfolio includes over 20 companies such as atai Life Sciences, Field Trip Health, Bexson Biomedical, and Reset Pharma. The firm’s leadership is guided by top-tier experts in the psychedelic space, including Co-Founder Tim Schlidt, who is passionate about expanding access to mental health treatments. They are supported by a renowned advisory board made up of thought leaders like Dr. Charles Nichols, a professor and pioneering researcher in psychedelics, and Dr. Julie Holland, a psychiatrist and author focused on drug policy reform and clinical research into psychedelic therapies. This interdisciplinary approach enables Palo Santo to navigate the complex regulatory and scientific challenges in this emerging industry. Palo Santo's strategy emphasizes not just the scientific advancement of psychedelics, but also their affordability and accessibility for patients. They aim to scale clinically effective treatments by investing in companies that are making significant strides in the mental health sector. Their goal is to bring psychedelic therapies into the mainstream, addressing the growing global mental health crisis with innovative, science-backed solutions.

Palumni VC is a Miami, Florida-based early-stage venture capital firm founded in 2020 by Founding Partner Luba Lesiva with a narrow, proprietary thesis: invest exclusively in the next generation of companies founded and led by Palantir alumni. SEC-registered as PALUMNI VC, LLC (Firm #321066), the firm draws on a private investor network of more than 600 operators, founders, and angels, almost all of them ex-Palantir, to serve as the connective tissue of the Palantir diaspora. The goal is to be the most value-add investor per dollar on the cap table of every portfolio company, through strategic introductions, operator-driven advice, and follow-on support along the full founder journey. Palumni is not constrained by stage, sector, or geography, though its sweet spot is high-signal seed and Series A rounds in software, analytics, AI and machine learning, enterprise SaaS, and HR and recruiting. Typical check sizes are $200,000, with an overall range of roughly $150,000 to $1 million. The firm also operates an AngelList syndicate to enable its alumni network to co-invest pro rata. Across 80 investments, named portfolio companies include Adyton, Kairos, Kolena, Kurtosis, Little Otter (children's mental health), Metaview (AI interviewing), and Mural (collaborative whiteboarding). The most recent publicly recorded investment is Digger, a software development applications company, in June 2025. Palumni VC's edge is sourcing: founders who are Palantir alumni have a demonstrated track record of building complex data and analytics infrastructure, and the firm's alumni network provides a pre-vetted funnel of high-caliber operators building their own companies.

Panacea Venture is a global healthcare-focused venture capital fund with a strong track record in early-stage life sciences investments. Spun out of Kleiner Perkins, Panacea specializes in building innovative companies that target unmet medical needs, particularly in biotech, therapeutics, and medical devices. Their investment scope spans cell and gene therapies, diagnostics, and emerging technologies like AI-driven healthcare solutions. With a global reach, Panacea has offices in Shanghai, Boston, and Silicon Valley, leveraging its cross-border expertise to tap into transformative healthcare innovations across North America and Asia. The firm is highly active, leading early-stage rounds and often taking board seats, while its venture operator model allows them to incubate and actively manage portfolio companies. Notable portfolio names include groundbreaking companies in immunotherapy and gene editing, such as TriArm Therapeutics and Kindstar Global. Panacea’s investment approach focuses on deep due diligence and long-term partnerships. They seek companies with strong scientific foundations and scalable technologies, preferring founders with deep domain expertise. The fund’s managing partner, James Huang, along with a diverse team of venture partners, brings over 100 years of combined experience in both venture capital and life sciences industries. They continue to focus on early-stage growth, with an emphasis on hands-on involvement to drive value from inception to public market success.

Panache Ventures is a leading Canadian venture capital firm specializing in early-stage investments, particularly at the pre-seed and seed stages. Founded in 2018, the firm has a strong national presence with offices in Vancouver, Calgary, Toronto, and Montreal. Panache Ventures focuses on supporting ambitious entrepreneurs across various sectors, including enterprise software, AI/ML, fintech, blockchain/web3, health tech, and climate tech. Panache Ventures' first fund raised over $58 million and invested in 100 companies, achieving notable exits such as fintech company Flinks and proptech company Lane. Their second fund, Panache Ventures II, closed at $100 million, with significant investments from Alberta Enterprise Corporation, Ontario Capital Growth Corporation, Investissement Québec, BMO Financial Group, and TELUS Ventures. This fund aims to double down on pre-seed and seed investments in Canadian technology startups, supporting around 20 new investments per year​. The firm is known for its commitment to diversity and inclusion, with 52% of its portfolio companies being led by persons of color and a rate of investment in women-led startups that is 1.8 times the national average for Canadian venture capital​​. Panache Ventures emphasizes a founder-friendly approach, providing extensive mentorship and support throughout the growth of their portfolio companies. Key team members include Chris Neumann, Scott Loong, Prashant Matta, and Patrick Lor, who collectively bring a wealth of experience and expertise to the firm.

Panakès Partners, based in Milan, is a leading venture capital firm specializing in life sciences. Founded by Diana Saraceni, who has over 20 years of experience in the VC industry, the firm focuses on early-stage startups and SMEs developing innovative technologies in biotech, diagnostics, and medical devices. Their portfolio includes notable investments like EndoStart and Diadem, reflecting their commitment to groundbreaking solutions in healthcare. Panakès primarily targets Europe and Israel, aiming to address significant unmet medical needs with a robust ESG framework. Their latest €175 million fund, the Purple Fund, emphasizes Series A investments, supporting around 15-18 companies with average checks ranging from €5 to €10 million. Known for leading rounds, Panakès actively engages with startups through a rigorous selection process, valuing sustainability and impactful health solutions. The team, led by Saraceni, brings extensive expertise and a strong network in the life sciences sector, bolstered by their participation in various national and international advisory boards. For entrepreneurs, Panakès is approachable via direct submissions to their email, fostering a transparent and accessible investment process.